SEC Form 4 · accession 0001179110-18-014192
IDERA PHARMACEUTICALS, INC. · IDRA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Carol Schafer
Director
Period of report
Dec 18, 2018
Accepted (ET)
Dec 20, 2018 · 5:25 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000861838
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Dec 19, 2018 | P | 5,000 | $3.3342 | A | 5,000 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F2 | $3.12 | Dec 18, 2018 | A | 23,000 | A | — | Dec 18, 2028 | Common Stock | 23,000 | 23,000 | D |
Explanation of responses
- F1The price reported represents the weighted average sales price of shares purchased in multiple transactions at prices ranging from $3.293 to $3.3705 per share. The reporting person hereby undertakes, upon the request of the Staff of the U.S. Securities and Exchange Commission, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.
- F2The option was granted under the Issuer's 2013 Stock Incentive Plan. The option vests and becomes exercisable over a three-year period commencing on December 18, 2018. Thirty-three percent (33%) of the underlying shares vest and become exercisable on December 18, 2019 (first anniversary of the date of grant) with the balance of the underlying shares vesting in eight equal quarterly installments over the remaining two years of the three-year period, subject to continued service with the Issuer. The option automatically becomes exercisable in full upon the occurrence of a change in control of the Issuer.